Spruce Biosciences price target raised to $8 from $7 at JMP Securities

JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Spruce Biosciences to $8 from $7 and keeps an Outperform rating on the shares. Spruce’s CAH readouts in both adults and children are on track for this half as interim data in PCOS patients stoke the firm’s interest in the full data and potential opportunity, the analyst tells investors in a research note. The firm would be a buyer of shares with multiple near-term tildacerfont readouts that could provide a boost.